ADAMIS PHARMACEUTICALS CORPORATION

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company. The Company is focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory diseases. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg, which is used in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more; and SYMJEPI (epinephrine) Injection 0.15mg, which is used in the treatment of anaphylaxis for patients weighing 33-65 pounds. Its other product candidates include ZIMHI (naloxone) Injection, which is used for the treatment of opioid overdose; and Tempol (APC-400), an investigational drug, which is used in the fields of COVID-19 infection, asthma, respiratory syncytial virus infection, and influenza infection. It also has a microbicide product candidate, named C31G.